⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REPL News
Replimune Group, Inc.
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights
globenewswire.com
MRK
BMY
AMGN
REPL
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Investors to Inquire about Securities Investigation
accessnewswire.com
REPL
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Investors to Reach Out
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group, Inc. (REPL) And Encourages Stockholders to Reach Out
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
accessnewswire.com
REPL
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Stockholders to Connect
accessnewswire.com
REPL
Replimune Group, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
globenewswire.com
REPL